Amsilarotene
- Generic Name
- Amsilarotene
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Registration Number
- NCT00756782
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00687596
- Locations
- 🇮🇹
I.R.C.C.S. San Matteo University Hospital, Golgi, Pavia, Italy
Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00667628
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National hospital organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT00077142
- Locations
- 🇺🇸
MD Anderson Cancer Center at University of Texas, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath